Ionis Pharmaceuticals Gains Momentum with Key Approvals and Pipeline Successes
Recent regulatory wins for Dawnzera in Europe and breakthrough therapy designations from the FDA, alongside positive Phase 3 data from a partner, bolster Ionis's late-stage portfolio. However, insider stock sales and a trimmed stake by a major investor highlight the ongoing challenge of converting scientific promise into sustained commercial success.